Puma Biotechnology | PBYI - Equity Capital And Reserves


Puma Biotechnology reported $115.27M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Daiichi Sankyo JPY 1.7T 38.53B Jun/2026
Exelixis USD 1.84B 91.99M Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Moderna USD 6.76B 647M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Takeda JPY 7.56T 215.7B Jun/2026
TG Therapeutics USD 604.08M 20.95M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026